Production (Stage)
Leap Therapeutics, Inc.
LPTX
$0.393
-$0.0022-0.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -0.23% | 2.48% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.63% | -12.14% | |||
| Operating Income | 1.63% | 12.14% | |||
| Income Before Tax | 0.77% | 10.96% | |||
| Income Tax Expenses | -- | -117.37% | |||
| Earnings from Continuing Operations | -0.03% | 15.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.03% | 15.10% | |||
| EBIT | 1.63% | 12.14% | |||
| EBITDA | 1.64% | 12.14% | |||
| EPS Basic | 1.50% | 13.92% | |||
| Normalized Basic EPS | 50.38% | -77.88% | |||
| EPS Diluted | 1.50% | 13.92% | |||
| Normalized Diluted EPS | 50.38% | -77.88% | |||
| Average Basic Shares Outstanding | 0.04% | 0.10% | |||
| Average Diluted Shares Outstanding | 0.04% | 0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||